Read the latest
MedTech & Biotech News
Regulatory Intelligence: Meeting the Demands of Today’s Global Regulatory Market
Regulatory Intelligence: Meeting the Demands of Today’s Global Regulatory Market The increase in global...
Read MoreThe Importance of High-Quality Communication in the Healthcare Setting
The Importance of High-Quality Communication in the Healthcare Setting According to a Commonwealth Fund...
Read MoreNew Resource Sheds Light on FDA CDRH Regulatory Focus
New Resource Sheds Light on FDA CDRH Regulatory Focus Device developers seeking insight into...
Read MoreBiden says America’s 'banking system is safe' after regulators back up all SVB deposits
Biden says America’s 'banking system is safe' after regulators back up all SVB deposits March...
Read MoreGSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy
GSK's $100M ADC bet in doubt after fatality in first trial of Mersana's cancer therapy...
Read MoreUK biopharma body praises bank for keeping doors open at life science startups by rescuing SVB UK
UK biopharma body praises bank for keeping doors open at life science startups by rescuing...
Read MoreSVB capital crunch sends biotechs on bank run
SVB capital crunch sends biotechs on bank run March 10, 2023 7:44 am https://www.fiercebiotech.com/biotech/biotech-bank-svbs-capital-crunch-sparks-bank-run-companies-huddle-consider-exposure
Read MoreAfter slimming down, Applied Molecular Transport no closer to taking UC drug into phase 3
After slimming down, Applied Molecular Transport no closer to taking UC drug into phase 3...
Read MoreVyne swings behind BET inhibitors, seeks partner for failed eczema drug
Vyne swings behind BET inhibitors, seeks partner for failed eczema drug March 10, 2023 4:55...
Read MoreOlema, prioritizing oral SERD, plans 25% head count cut, pulls back from early-stage work
Olema, prioritizing oral SERD, plans 25% head count cut, pulls back from early-stage work March...
Read MoreChutes & Ladders—Biogen names Stelios Papadopoulos' successor
Chutes & Ladders—Biogen names Stelios Papadopoulos' successor March 9, 2023 12:35 pm https://www.fiercebiotech.com/biotech/chutes-ladders-biogen-names-papadopoulos-successor
Read MoreSmartphone Photos to Detect Anemia
<!– Medical Innovation Exchange March 9, 2023 7:40 am Smartphone Photos to Detect Anemia
Read MoreUltrasound Catheter to Treat Hypertension
<!– Medical Innovation Exchange March 9, 2023 7:18 am Ultrasound Catheter to Treat Hypertension
Read MoreVertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic
Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic March 9,...
Read MoreFDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns
FDA placed hold on Fulcrum's sickle cell therapy over hematological malignancy concerns March 9, 2023...
Read MoreLilly's 10-year bet on treating Alzheimer's before symptoms start ends in failure
Lilly's 10-year bet on treating Alzheimer's before symptoms start ends in failure March 9, 2023...
Read MoreNeoleukin, old ending: De novo protein player lays off 70% of staff, searches for strategic alternative
Neoleukin, old ending: De novo protein player lays off 70% of staff, searches for strategic...
Read MoreInhibikase checks off another clinical hold, readying phase 2 trial for patients with rare brain disease
Inhibikase checks off another clinical hold, readying phase 2 trial for patients with rare brain...
Read MoreAll systems go for Mesoblast’s 2nd attempt to secure allogeneic cell therapy FDA win
All systems go for Mesoblast’s 2nd attempt to secure allogeneic cell therapy FDA win March...
Read MoreFresh Tracks may disappear as biotech mulls sale to continue autoimmune pipeline
Fresh Tracks may disappear as biotech mulls sale to continue autoimmune pipeline March 8, 2023...
Read MoreE-labeling: The Road to Reduced Medical Device Packaging Material
E-labeling: The Road to Reduced Medical Device Packaging Material In the consumer world, it’s...
Read MoreRedx stung by porcupine inhibitor flop in biliary tract cancer, setting biotech back before Jounce merger
Redx stung by porcupine inhibitor flop in biliary tract cancer, setting biotech back before Jounce...
Read MoreChasing Moderna, Merck pays $50M to join race to develop cancer-preventing vaccine
Chasing Moderna, Merck pays $50M to join race to develop cancer-preventing vaccine March 8, 2023...
Read MoreIncreasing Momentum in Medical Device Security
Increasing Momentum in Medical Device Security In 2021, an employee at Ireland’s public health...
Read MoreBlackHägen Design Announces Death of Founder and Human Factors Engineer Sean Hägen
BlackHägen Design Announces Death of Founder and Human Factors Engineer Sean Hägen With deep...
Read MoreChiesi offers Affibody breath of fresh air in respiratory disease deal worth up to $637M
Chiesi offers Affibody breath of fresh air in respiratory disease deal worth up to $637M...
Read MoreProtagonist's story turns for the better as J&J-partnered psoriasis med clears lesions in midphase trial
Protagonist's story turns for the better as J&J-partnered psoriasis med clears lesions in midphase trial...
Read MoreFlagship fledging fetches $50M to fire drugs at specific organs, fix on-target, off-tissue toxicity
Flagship fledging fetches $50M to fire drugs at specific organs, fix on-target, off-tissue toxicity March...
Read MoreThird Rock, J&J spinout Rapport arrives with $100M and ambition to transform precision neuroscience
Third Rock, J&J spinout Rapport arrives with $100M and ambition to transform precision neuroscience March...
Read MoreImmuneering, saving cash for universal RAS candidate, suspends neuroscience programs
Immuneering, saving cash for universal RAS candidate, suspends neuroscience programs March 7, 2023 2:06 am...
Read MoreArmed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med
Armed with $60M series A and Lilly's backing, Volastra enters clinic via Amgen cancer med...
Read MoreRallybio reassembles behind version 2.0 of fetal blood disorder med
Rallybio reassembles behind version 2.0 of fetal blood disorder med March 6, 2023 6:57 am...
Read MoreAclaris stock halves after phase 2a skin study misses goals
Aclaris stock halves after phase 2a skin study misses goals March 6, 2023 6:39 am...
Read MoreTo 'keep pace with viral evolution,' Invivyd is also evolving (again)
To 'keep pace with viral evolution,' Invivyd is also evolving (again) March 6, 2023 6:16...
Read More2 months after depression fail, Atai lays off 30% and reviews pipeline again
2 months after depression fail, Atai lays off 30% and reviews pipeline again March 6,...
Read MoreMerck’s cardiovascular future takes shape as sotatercept overachieves, PCSK9 inhibitor passes phase 2
Merck’s cardiovascular future takes shape as sotatercept overachieves, PCSK9 inhibitor passes phase 2 March 6,...
Read MoreAdaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline
Adaptimmune absorbs TCR² to extend cash runway and broaden T-cell pipeline March 6, 2023 4:40...
Read MoreHarbour ships phase 3 data to take lead over argenx, J&J and UCB in Chinese autoimmune race
Harbour ships phase 3 data to take lead over argenx, J&J and UCB in Chinese...
Read MoreIncyte’s LIMBER lumbers to early end as analysis shows Jakafi cancer combo destined to fail
Incyte’s LIMBER lumbers to early end as analysis shows Jakafi cancer combo destined to fail...
Read MoreBig Decisions – Reviewing FDA Advisory Committee Outcomes Since 2020
In January we took a look at FDA Advisory Committees (AdComms) – FDA AdComms –...
Read MoreNovartis ready to head for deep space with Voyager after a year 'kicking the tires'
Novartis ready to head for deep space with Voyager after a year 'kicking the tires'...
Read MoreVeru’s EUA ambitions crash after FDA declines to authorize its COVID treatment
Veru’s EUA ambitions crash after FDA declines to authorize its COVID treatment March 3, 2023...
Read MoreBig Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report
Big Pharma regained ‘mojo’ last year, but biotech valuations remain ‘precarious’: report March 3, 2023...
Read MorePraxis share price halved after essential tremor fail, but biotech still plans phase 3
Praxis share price halved after essential tremor fail, but biotech still plans phase 3 March...
Read MoreAeglea's latest layoffs, pipeline cull curb spending, but cash crunch still on the cards
Aeglea's latest layoffs, pipeline cull curb spending, but cash crunch still on the cards March...
Read MoreChutes & Ladders—Billy Dunn departs FDA neuroscience team after 18 years
Chutes & Ladders—Billy Dunn departs FDA neuroscience team after 18 years March 2, 2023 10:54...
Read MoreManaging Legacy Technology Security
Managing Legacy Technology Security To help address the cybersecurity risks of legacy devices used...
Read MoreAlpha TAU Killing Tumors With Highly Targeted Alpha Radiation
<!– Medical Innovation Exchange March 2, 2023 6:50 am Alpha TAU Killing Tumors With Highly...
Read MoreA duo of deals sees Avenue secure rare disease med while Allist lands cancer drug
A duo of deals sees Avenue secure rare disease med while Allist lands cancer drug...
Read MoreNovo Nordisk recruits new staff, lays off others as US R&D consolidated in Boston
Novo Nordisk recruits new staff, lays off others as US R&D consolidated in Boston March...
Read MoreMorphoSys, once a discovery powerhouse, exits preclinical R&D, lays off staff to focus cash on clinic
MorphoSys, once a discovery powerhouse, exits preclinical R&D, lays off staff to focus cash on...
Read MoreInovio’s endpoint switcheroo backfires as phase 3 misses on new measure, hits on old
Inovio’s endpoint switcheroo backfires as phase 3 misses on new measure, hits on old March...
Read MoreFlamingo folds Dynacure into its flamboyance to wade through biotech markets together
Flamingo folds Dynacure into its flamboyance to wade through biotech markets together March 1, 2023...
Read MoreFDA advisors support efficacy and safety of GSK's RSV vaccine with more confidence than Pfizer rival
FDA advisors support efficacy and safety of GSK's RSV vaccine with more confidence than Pfizer...
Read MoreConfo hands baton to Lilly for non-opioids pain med development in $40M upfront deal
Confo hands baton to Lilly for non-opioids pain med development in $40M upfront deal March...
Read MoreBacteria Create Protein Nanowires for Biosensing
<!– Medical Innovation Exchange March 1, 2023 7:55 am Bacteria Create Protein Nanowires for Biosensing
Read MorePatient-Specific Soft Robotic Heart Replicas for Treatment Planning
<!– Medical Innovation Exchange March 1, 2023 6:54 am Patient-Specific Soft Robotic Heart Replicas for...
Read MoreNew Ambrx CEO spies path for ousted breast cancer med as partner posts encouraging phase 2 results
New Ambrx CEO spies path for ousted breast cancer med as partner posts encouraging phase...
Read MoreDeveloping an Effective and Sustainable Regulatory Strategy for Today’s Global Market
Developing an Effective and Sustainable Regulatory Strategy for Today’s Global Market Global regulatory demands...
Read MoreRegulating Point of Care Printed Devices
Regulating Point of Care Printed Devices The use of 3D printing for medical devices...
Read MoreG1 sheds staff, while Sorrento WARNs of cuts amid torrential downpour of industry layoffs
G1 sheds staff, while Sorrento WARNs of cuts amid torrential downpour of industry layoffs March...
Read MorePMW sidelines two programs as lead tumor suppressor candidate picks up pace in clinic
PMW sidelines two programs as lead tumor suppressor candidate picks up pace in clinic March...
Read MoreVertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy
Vertex pays ImmunoGen $15M to use antibody-drug conjugates to improve CRISPR therapy March 1, 2023...
Read MoreAtea dumps dengue drug as ‘unevaluable’ endpoint causes timelines, forecast costs to spiral
Atea dumps dengue drug as ‘unevaluable’ endpoint causes timelines, forecast costs to spiral March 1,...
Read MoreChroma bags another nine-digit financing, taking $135M series B to bolster epigenetic-focused platform
Chroma bags another nine-digit financing, taking $135M series B to bolster epigenetic-focused platform February 28,...
Read MoreSarepta’s DMD gene therapy inches closer to market as FDA declines to hold advisory meeting
Sarepta’s DMD gene therapy inches closer to market as FDA declines to hold advisory meeting...
Read MorePfizer's RSV vaccine wins support of FDA panel despite lingering safety and efficacy questions
Pfizer's RSV vaccine wins support of FDA panel despite lingering safety and efficacy questions February...
Read MoreFlex Medical Molding Achieves MedAccred Plastics Injection Molding Accreditation
Flex Medical Molding Achieves MedAccred Plastics Injection Molding Accreditation Flex Medical Molding (Shenzhen) Co.,...
Read MoreNeuroimmune Modulation for Inflammatory Disease: Interview with Dr. Simhambhatla, President and CEO of SetPoint Medical
<!– Medical Innovation Exchange February 28, 2023 10:17 am Neuroimmune Modulation for Inflammatory Disease: Interview...
Read MoreAlzheimer's meds are here. But for the Down syndrome community, it's still the 1980s
Alzheimer's meds are here. But for the Down syndrome community, it's still the 1980s February...
Read MoreProtecting Innovation in FemTech
Protecting Innovation in FemTech As opportunities for innovation and investment in women’s healthcare accelerate,...
Read MoreOvarian Organoids to Study Reproductive Health
<!– Medical Innovation Exchange February 28, 2023 8:21 am Ovarian Organoids to Study Reproductive Health
Read MoreFDA flags Guillain-Barré risks for GSK, Pfizer RSV shots, but just one will need safety trial
FDA flags Guillain-Barré risks for GSK, Pfizer RSV shots, but just one will need safety...
Read MoreJunshi’s lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in growth market
Junshi’s lipid lowering drug hits phase 3 goals, teeing up challenge to Amgen, Sanofi in...
Read MoreLatest biotech-on-biotech merger sees aimless Adamis snapped up by DMK
Latest biotech-on-biotech merger sees aimless Adamis snapped up by DMK February 28, 2023 1:55 am...
Read MoreAptinyx, reeling from series of setbacks, dumps dementia drug, stops PTSD trial after phase 2 flop
Aptinyx, reeling from series of setbacks, dumps dementia drug, stops PTSD trial after phase 2...
Read MoreTheravance takes another blow, but vows to fight on with slimmed headcount and new trial
Theravance takes another blow, but vows to fight on with slimmed headcount and new trial...
Read MoreAstraZeneca grows Canadian snowshoe print with 500 new jobs and rare disease hub
AstraZeneca grows Canadian snowshoe print with 500 new jobs and rare disease hub February 27,...
Read MoreDunn with the FDA: head of agency's neuroscience unit to depart
Dunn with the FDA: head of agency's neuroscience unit to depart February 27, 2023 7:53...
Read MoreWearable Device Senses When Vocal Fatigue Sets in
<!– Medical Innovation Exchange February 27, 2023 7:27 am Wearable Device Senses When Vocal Fatigue...
Read MoreHIV Vaccine Candidate Stops Virus As it Enters Body
<!– Medical Innovation Exchange February 27, 2023 6:59 am HIV Vaccine Candidate Stops Virus As...
Read MoreCSL, seeking to stall Takeda drug, links antibody to rare disease benefits and plans global filings
CSL, seeking to stall Takeda drug, links antibody to rare disease benefits and plans global...
Read MoreMonths after going public, Apexigen lays of 55% of staff and considers exit routes
Months after going public, Apexigen lays of 55% of staff and considers exit routes February...
Read MoreKeytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody
Keytruda killer: Chipscreen bags Chinese rights to Biocytogen's bispecific antibody February 27, 2023 4:33 am...
Read MoreAfter spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year
After spending $6.5B for Momenta, J&J readies 'pipeline in a product' for pivotal year February...
Read MoreWhat can bats, naked mole rats and Jaws tell us about human biology? Paratus is on a $100M mission to find out
What can bats, naked mole rats and Jaws tell us about human biology? Paratus is...
Read MoreDestiny seals C. diff therapy's phase 3 fate with Sebela
Destiny seals C. diff therapy's phase 3 fate with Sebela February 24, 2023 5:35 am...
Read MoreFulcrum's clinical hold caps off tough week for sickle cell drug development
Fulcrum's clinical hold caps off tough week for sickle cell drug development February 24, 2023...
Read MoreObsEva demolishes US C-suite in latest cost-cutting measures as Nasdaq delisting looms
ObsEva demolishes US C-suite in latest cost-cutting measures as Nasdaq delisting looms February 24, 2023...
Read MoreNektar’s bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink
Nektar’s bitter pill: Phase 2 fail ends Lilly-partnered lupus program and prompts eczema rethink February...
Read MoreNovartis punts Pliant-partnered NASH prospect amid pipeline prioritization pivot
Novartis punts Pliant-partnered NASH prospect amid pipeline prioritization pivot February 24, 2023 1:08 am https://www.fiercebiotech.com/biotech/novartis-punts-pliant-partnered-nash-prospect-amid-pipeline-prioritization-pivot
Read MoreChutes & Ladders—Roivant founder ditches board for White House bid
Chutes & Ladders—Roivant founder ditches board for White House bid February 23, 2023 4:22 pm...
Read MoreElectrostatic Face Mask Self-Charges with Breathing
<!– Medical Innovation Exchange February 23, 2023 12:55 pm Electrostatic Face Mask Self-Charges with Breathing
Read MoreNextGen COVID-19 Antibodies Destroy Spike Protein
<!– Medical Innovation Exchange February 23, 2023 12:25 pm NextGen COVID-19 Antibodies Destroy Spike Protein
Read MoreSangamo shelves sickle cell therapy, joining rivals forced to rethink development plans
Sangamo shelves sickle cell therapy, joining rivals forced to rethink development plans February 23, 2023...
Read MoreFDA Seeks Industry Collaboration on Medical Device Active Surveillance System
FDA Seeks Industry Collaboration on Medical Device Active Surveillance System The FDA is seeking...
Read MoreGraphite pencils out sickle cell therapy after adverse event, cutting half of workforce loose
Graphite pencils out sickle cell therapy after adverse event, cutting half of workforce loose February...
Read MoreInfinity pools resources with MEI Pharma in oncology-focused merger
Infinity pools resources with MEI Pharma in oncology-focused merger February 23, 2023 7:17 am https://www.fiercebiotech.com/biotech/infinity-pools-resources-mei-pharma-oncology-focused-merger
Read MorePrilenia searches for positive signs as oral ALS drug fails to improve disease severity in phase 2
Prilenia searches for positive signs as oral ALS drug fails to improve disease severity in...
Read MoreAfter a tough year, VBL merges with Notable Labs
After a tough year, VBL merges with Notable Labs February 23, 2023 6:26 am https://www.fiercebiotech.com/biotech/vbl-merges-notable-labs-latter-reels-103m
Read MoreModerna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data
Moderna, on its back foot, reassures investors on flu vaccine after mixed phase 3 data...
Read MoreAs Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market 'wide open'
As Novartis pulls back from legacy sickle cell program, Intellia CEO calls the market 'wide...
Read MoreLayoffs not letting up: Impel, Cybin, EQRx all trim head counts with eyes on saving cash
Layoffs not letting up: Impel, Cybin, EQRx all trim head counts with eyes on saving...
Read MoreJounce pounces on exit opportunity, laying off 57% of staff alongside reverse merger with Redx
Jounce pounces on exit opportunity, laying off 57% of staff alongside reverse merger with Redx...
Read MoreAstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal
AstraZeneca doubles down on hot cancer target, paying $63M for ADC months after bispecific deal...
Read MoreGraphite pencils out sickle cell therapy after patient death, cutting half of workforce loose
Graphite pencils out sickle cell therapy after patient death, cutting half of workforce loose February...
Read MoreCapsida reels in another Big Pharma deal, this time diving into eye disease with AbbVie
Capsida reels in another Big Pharma deal, this time diving into eye disease with AbbVie...
Read MoreFallout from Quantum Genomics' phase 3 fail claims top executives as biotech searches for a future
Fallout from Quantum Genomics' phase 3 fail claims top executives as biotech searches for a...
Read MoreBioCryst hits another hurdle, delays trial for its 1 remaining clinical candidate
BioCryst hits another hurdle, delays trial for its 1 remaining clinical candidate February 22, 2023...
Read More'We beg you': Biotechs plead for help and funds to find long COVID treatments
'We beg you': Biotechs plead for help and funds to find long COVID treatments February...
Read MoreAfter last-ditch effort, cellular medicine biotech Rubius moves to dissolve
After last-ditch effort, cellular medicine biotech Rubius moves to dissolve February 22, 2023 5:14 am...
Read MoreAiling Aileron enters endgame as breast cancer data trigger layoffs and search for a buyer
Ailing Aileron enters endgame as breast cancer data trigger layoffs and search for a buyer...
Read MoreKinnate buys OrbiMed and Foresite's stakes in cancer venture, paying $24M to go solo in China
Kinnate buys OrbiMed and Foresite's stakes in cancer venture, paying $24M to go solo in...
Read MoreFrom Roivant to the White House on anti-woke agenda: Ramaswamy unveils presidential bid
From Roivant to the White House on anti-woke agenda: Ramaswamy unveils presidential bid February 22,...
Read MoreModerna's latest genomics move sees it team up with Life Edit to develop new gene editing therapies
Moderna's latest genomics move sees it team up with Life Edit to develop new gene...
Read MoreMedTech Developers Can Improve Surgical Workflows Through Thoughtful Innovation
MedTech Developers Can Improve Surgical Workflows Through Thoughtful Innovation A surgeon’s workflow inside of...
Read MoreAkebia says FDA staffing constraints are throwing a roadblock into appeal process
Akebia says FDA staffing constraints are throwing a roadblock into appeal process February 21, 2023...
Read MorePfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi
Pfizer's maternal RSV vaccine filing gets priority review, setting up showdown with AstraZeneca, Sanofi February...
Read MoreBridge holds firm despite placebo beating drug in midphase ulcerative colitis trial
Bridge holds firm despite placebo beating drug in midphase ulcerative colitis trial February 21, 2023...
Read MoreWith $135M in fresh funds, Hemab aims to leapfrog drug development for neglected blood disorders
With $135M in fresh funds, Hemab aims to leapfrog drug development for neglected blood disorders...
Read MoreBlockchain Can Solve Pharma’s Costly Data Integrity Problem
Blockchain Can Solve Pharma’s Costly Data Integrity Problem In the pharmaceutical industry, quality data...
Read MoreCRO Avania Acquires MAXIS
CRO Avania Acquires MAXIS Avania, a global medical technology contract research organization (CRO), has acquired MAXIS,...
Read MoreRaman-Based Urine Sensor Detects Cancer Metabolites
<!– Medical Innovation Exchange February 20, 2023 7:57 am Raman-Based Urine Sensor Detects Cancer Metabolites
Read MoreAstellas has menopause accelerated approval ambition thwarted by FDA at last minute
Astellas has menopause accelerated approval ambition thwarted by FDA at last minute February 20, 2023...
Read MoreAssignor Estoppel: Protecting Your Patent Rights
Assignor Estoppel: Protecting Your Patent Rights The centuries-old common law doctrine of assignor estoppel...
Read MoreExclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions
<!– Medical Innovation Exchange February 17, 2023 7:12 am Exclusive Look at HandX Robotic-Assisted Surgical...
Read MorePersonalized CAR-T Cell Therapy
<!– Medical Innovation Exchange February 17, 2023 6:41 am Personalized CAR-T Cell Therapy
Read MorePfizer pulls 50% of people from phase 3 Lyme disease study for GCP violations at US trial sites
Pfizer pulls 50% of people from phase 3 Lyme disease study for GCP violations at...
Read MoreModerna checks a few boxes in phase 3 mRNA flu shot trial, but misses on B strains and safety
Moderna checks a few boxes in phase 3 mRNA flu shot trial, but misses on...
Read MoreChutes & Ladders—John Reed jumps Sanofi ship, boards J&J team
Chutes & Ladders—John Reed jumps Sanofi ship, boards J&J team February 16, 2023 10:19 am...
Read MoreIngestible Sensor Reveals Gastric Motility
<!– Medical Innovation Exchange February 16, 2023 8:31 am Ingestible Sensor Reveals Gastric Motility
Read MoreAutomated Mass Spec Technique to Detect Antidepressants
<!– Medical Innovation Exchange February 16, 2023 7:56 am Automated Mass Spec Technique to Detect...
Read MoreMonths after kidney transplant trial resumes, Talaris discontinues program and cuts third of workforce
Months after kidney transplant trial resumes, Talaris discontinues program and cuts third of workforce February...
Read More'It's the right call': GSK expresses no regrets on abandoning cell therapy as oligo strategy heats up
'It's the right call': GSK expresses no regrets on abandoning cell therapy as oligo strategy...
Read MoreTheratechnologies assembles science team to retool solid tumor trial after clinical hold
Theratechnologies assembles science team to retool solid tumor trial after clinical hold February 16, 2023...
Read MoreBy merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy
By merging with struggling Erytech, Pherecydes spies opportunity to boost AMR strategy February 16, 2023...
Read MoreNewron's shares accelerate as one-year schizophrenia data boosts chances of historic approval
Newron's shares accelerate as one-year schizophrenia data boosts chances of historic approval February 16, 2023...
Read MoreMerck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target
Merck KGaA, spying a major market, pays Aqilion €10M to tackle tough autoimmune target February...
Read MoreOn hunt for better gene med delivery, Aera exits stealth with $193M and Alnylam vet at helm
On hunt for better gene med delivery, Aera exits stealth with $193M and Alnylam vet...
Read MoreGSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal trial
GSK vaccine R&D head touts consistency of RSV data but is mum on restarting maternal...
Read MoreArrowhead’s $3.7B J&J deal is done, CEO says, after ‘out of the blue’ NASH decision
Arrowhead’s $3.7B J&J deal is done, CEO says, after ‘out of the blue’ NASH decision...
Read MoreAcoustic Stimulation for Insomnia
<!– Medical Innovation Exchange February 15, 2023 7:42 am Acoustic Stimulation for Insomnia
Read MoreAfter several flops, Merck exec stands by aggressive Keytruda prostate cancer program
After several flops, Merck exec stands by aggressive Keytruda prostate cancer program February 15, 2023...
Read MoreSelf-Assembling Peptides as a Bioink
<!– Medical Innovation Exchange February 15, 2023 6:56 am Self-Assembling Peptides as a Bioink
Read MoreBiogen's brand-new CEO shuns 'desperation factor' but signals major business development ahead
Biogen's brand-new CEO shuns 'desperation factor' but signals major business development ahead February 15, 2023...
Read MoreJ&J returns NASH med back to Arrowhead's quiver with Hep B still in limbo
J&J returns NASH med back to Arrowhead's quiver with Hep B still in limbo February...
Read MoreAlloVir's cell therapy tackles infection in midphase kidney transplant trial
AlloVir's cell therapy tackles infection in midphase kidney transplant trial February 15, 2023 5:17 am...
Read MoreConcert persuades FDA to keep breakthrough tag for alopecia therapy despite Lilly's arrival
Concert persuades FDA to keep breakthrough tag for alopecia therapy despite Lilly's arrival February 15,...
Read MoreBiogen bails on BTK race just 19 months after placing $125M bet
Biogen bails on BTK race just 19 months after placing $125M bet February 15, 2023...
Read MoreAutomated Feeding Platform to Study Mosquito Disease Transmission
<!– Medical Innovation Exchange February 14, 2023 8:20 am Automated Feeding Platform to Study Mosquito...
Read MoreElectrochemical Sensor for Detailed SARS-CoV-2 Immunity Data
<!– Medical Innovation Exchange February 14, 2023 7:01 am Electrochemical Sensor for Detailed SARS-CoV-2 Immunity...
Read MoreNew biotech VC takes off with $520M and a flight deck stacked with big-name investors ready to serve
New biotech VC takes off with $520M and a flight deck stacked with big-name investors...
Read MoreSesen sweetens Carisma deal to win over rogue investors in time for Valentine's Day
Sesen sweetens Carisma deal to win over rogue investors in time for Valentine's Day February...
Read MoreNanowire Assay Detects Brain Tumors from Urine
<!– Medical Innovation Exchange February 14, 2023 6:37 am Nanowire Assay Detects Brain Tumors from...
Read MoreMedical Device Computational Modeling and Simulation Reports Highlights Best Uses and Barriers to Adoption
Medical Device Computational Modeling and Simulation Reports Highlights Best Uses and Barriers to Adoption ...
Read MorePharnext ditches Alzheimer’s plans, saying more development would be too costly
Pharnext ditches Alzheimer’s plans, saying more development would be too costly February 14, 2023 5:59...
Read MoreSoligenix's stock sinks 38% after FDA refuses to consider lymphoma therapy application
Soligenix's stock sinks 38% after FDA refuses to consider lymphoma therapy application February 14, 2023...
Read MoreReplay rolls again, creating TCR-NK cell therapy startup with MD Anderson to close in on clinic
Replay rolls again, creating TCR-NK cell therapy startup with MD Anderson to close in on...
Read MoreGSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners
GSK nixes next-gen COVID-19 antibody collaboration, leaving Vir to fly solo, seek new partners February...
Read MoreCullinan sets sail toward U.S. with novel bispecific from Harbour BioMed for $25M in cash
Cullinan sets sail toward U.S. with novel bispecific from Harbour BioMed for $25M in cash...
Read MoreIntegrating Games into Medical Devices To Improve Patient Outcomes
Integrating Games into Medical Devices To Improve Patient Outcomes Digital games are a part...
Read MoreAddressing the next wave of COVID-19 through a new approach to vaccines
Addressing the next wave of COVID-19 through a new approach to vaccines February 13, 2023...
Read MoreFacilitating Increased Digital Monitoring
Facilitating Increased Digital Monitoring Some years ago, a visit to a doctor’s office or...
Read More3D Bioengineered Skin Grafts Fit Complex Anatomy
<!– Medical Innovation Exchange February 13, 2023 8:29 am 3D Bioengineered Skin Grafts Fit Complex...
Read More3 years after rejecting $1B buyout, Sorrento files for bankruptcy amid legal battles
3 years after rejecting $1B buyout, Sorrento files for bankruptcy amid legal battles February 13,...
Read MoreFrequency falters after phase 2 ear infection fail, axing 2 assets and 55% of staff
Frequency falters after phase 2 ear infection fail, axing 2 assets and 55% of staff...
Read MoreEna slices data to claim flu success in phase 2 and nasal spray's wide-ranging potential
Ena slices data to claim flu success in phase 2 and nasal spray's wide-ranging potential...
Read MoreOn the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev
On the turnaround trail, tiny Corbus pays $7.5M for rival to Seagen's oncology ADC Padcev...
Read MoreReed relinquishes R&D reins at Sanofi to pursue new opportunity, sparking race to find successor
Reed relinquishes R&D reins at Sanofi to pursue new opportunity, sparking race to find successor...
Read MoreBroadening the Commercialization Partnership
Broadening the Commercialization Partnership February 10, 2023 10:44 am https://www.fiercebiotech.com/sponsored/broadening-commercialization-partnership
Read MoreBlueprint told to stop sketching as FDA slaps partial hold on phase 1/2 trial
Blueprint told to stop sketching as FDA slaps partial hold on phase 1/2 trial February...
Read MoreFaced with safety issues over inflammation drug, AstraZeneca spinout Aristea closes shop
Faced with safety issues over inflammation drug, AstraZeneca spinout Aristea closes shop February 10, 2023...
Read MoreMineralys, amid signs of thawing IPO market, upsizes offering to raise $192M for race with AstraZeneca
Mineralys, amid signs of thawing IPO market, upsizes offering to raise $192M for race with...
Read MoreEliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team
Eliem drops depression drug, ending pursuit of Biogen-Sage and laying off 55% of team February...
Read MoreChutes & Ladders—Former Roche pharma chief tapped to be new Bayer CEO
Chutes & Ladders—Former Roche pharma chief tapped to be new Bayer CEO February 9, 2023...
Read MoreAntibacterial Smart Sutures Visible in CT Scans
<!– Medical Innovation Exchange February 9, 2023 8:34 am Antibacterial Smart Sutures Visible in CT...
Read More'Expect us to act' on M&A, AbbVie CEO says as company plots post-Humira plans
'Expect us to act' on M&A, AbbVie CEO says as company plots post-Humira plans February...
Read MoreVoice-Activated Sample Prep for Safer Handling
<!– Medical Innovation Exchange February 9, 2023 8:03 am Voice-Activated Sample Prep for Safer Handling
Read MoreTerahertz Spectroscopy to Assess Severity of Skin Burns
<!– Medical Innovation Exchange February 9, 2023 7:46 am Terahertz Spectroscopy to Assess Severity of...
Read MoreDespite rapidly emptying pipeline, AstraZeneca stays loyal to vaccine, immune therapy business
Despite rapidly emptying pipeline, AstraZeneca stays loyal to vaccine, immune therapy business February 9, 2023...
Read MoreMagenta's C-suite heads out the door with 85% of staff as closing process gets underway
Magenta's C-suite heads out the door with 85% of staff as closing process gets underway...
Read MoreAstraZeneca deals another blow to IL-12, dumping therapy to follow BMS, Merck KGaA out of race
AstraZeneca deals another blow to IL-12, dumping therapy to follow BMS, Merck KGaA out of...
Read MoreAligos' hep B functional cure dream fizzles out as cash crunch and layoffs force focus on NASH, COVID-19
Aligos' hep B functional cure dream fizzles out as cash crunch and layoffs force focus...
Read MoreTalent, Training and Scientific Infrastructure. All in NC.
Talent, Training and Scientific Infrastructure. All in NC. February 8, 2023 2:42 pm https://www.fiercebiotech.com/sponsored/talent-training-and-scientific-infrastructure-all-nc
Read MoreThe Power of Visuals
The Power of Visuals According to the Ebbinghaus Forgetting Curve, humans forget approximately 50%...
Read MoreFocused Ultrasound Releases Brain Biomarkers
<!– Medical Innovation Exchange February 8, 2023 7:14 am Focused Ultrasound Releases Brain Biomarkers
Read MoreHydrogel Cell Carrier for Fistula Healing
<!– Medical Innovation Exchange February 8, 2023 7:03 am Hydrogel Cell Carrier for Fistula Healing
Read MoreBottlebrush Particle for Synergistic Drug Combinations
<!– Medical Innovation Exchange February 8, 2023 6:50 am Bottlebrush Particle for Synergistic Drug Combinations
Read MoreHarnessing the Potential of LinkedIn for MedTech Professionals
Harnessing the Potential of LinkedIn for MedTech Professionals At some point since the start...
Read MoreAfter pandemic breather, Big Pharma sees drug development costs rise and returns sink: report
After pandemic breather, Big Pharma sees drug development costs rise and returns sink: report February...
Read MorePreparing for next pandemic, Korea's SK pumps $261M into vaccine R&D site
Preparing for next pandemic, Korea's SK pumps $261M into vaccine R&D site February 8, 2023...
Read MoreRegor gets permission to glimpse Pfizer's FBI communique in GLP-1 trade secrets dispute
Regor gets permission to glimpse Pfizer's FBI communique in GLP-1 trade secrets dispute February 8,...
Read MoreVistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending FDA talks
Vistagen, jittery after seeing rivals fail, pauses plan to restart phase 3 anxiety trial pending...
Read MoreBIO: Big Pharma offers menu of partnering options, but biotechs want licensing entrée
BIO: Big Pharma offers menu of partnering options, but biotechs want licensing entrée February 7,...
Read MoreAs J&J quietly overhauls R&D, Arrowhead waits for news on RNAi hepatitis B therapy
As J&J quietly overhauls R&D, Arrowhead waits for news on RNAi hepatitis B therapy February...
Read MorePRI Establishes Working Group to Improve Medical Device Quality and Supply Chain Resiliency
PRI Establishes Working Group to Improve Medical Device Quality and Supply Chain Resiliency The...
Read MoreChin Named Chief Financial Officer of Akido
Chin Named Chief Financial Officer of Akido Eric Chin is the new Chief Financial...
Read MoreFDA’s Oncology Center of Excellence slowed launch of new projects in 2022 to focus on trial modernization
FDA’s Oncology Center of Excellence slowed launch of new projects in 2022 to focus on...
Read MoreNeural Chip Detects, Suppresses Neurological Symptoms
<!– Medical Innovation Exchange February 7, 2023 6:40 am Neural Chip Detects, Suppresses Neurological Symptoms
Read MoreAntibacterial Peptide Spray Safe for Use on Wounds
<!– Medical Innovation Exchange February 7, 2023 6:22 am Antibacterial Peptide Spray Safe for Use...
Read More